Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr83.80 SEK
Change Today -1.00 / -1.18%
Volume 1.6M
EKTAB On Other Exchanges
Symbol
Exchange
OTC US
Stockholm
OTC US
Frankfurt
As of 11:29 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

elekta ab-b shs (EKTAB) Snapshot

Open
kr84.80
Previous Close
kr84.80
Day High
kr84.90
Day Low
kr82.80
52 Week High
05/16/14 - kr94.71
52 Week Low
10/16/14 - kr63.95
Market Cap
32.1B
Average Volume 10 Days
1.9M
EPS TTM
kr2.69
Shares Outstanding
368.6M
EX-Date
08/29/14
P/E TM
31.2x
Dividend
kr1.50
Dividend Yield
2.39%
Current Stock Chart for ELEKTA AB-B SHS (EKTAB)

Related News

No related news articles were found.

elekta ab-b shs (EKTAB) Related Businessweek News

No Related Businessweek News Found

elekta ab-b shs (EKTAB) Details

Elekta AB (publ), develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend sytem for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualize tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; and METRIQ, a cancer registry data solution. It also offers installation and implementation, service and support, remote, upgrades and accessories, and financial solutions, as well as training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

3,802 Employees
Last Reported Date: 03/4/15
Founded in 1972

elekta ab-b shs (EKTAB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

elekta ab-b shs (EKTAB) Key Developments

Elekta to Deliver Advanced Cancer Management Solutions to Providence Health & Services

Elekta announced that Providence Health & Services (Renton, Washington, USA) has ordered multiple Elekta cancer management solutions, including radiation therapy systems and upgrades, oncology information systems and multiyear service contracts for its hospitals, clinics and other health care facilities in Washington, Alaska, California, Montana and Oregon. In the agreement, Providence Health & Services will acquire several Versa HD™ systems, Elekta’s most advanced radiation therapy system (linear accelerator), featuring sophisticated beam shaping technology combined with high dose rate delivery. Versa HD is designed to give clinicians the flexibility to deliver conventional therapies to treat a wide range of small and large tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision. In addition, Elekta will provide upgrades to several existing Elekta systems, including the integration of Agility™ 160-leaf multileaf collimator (MLC) and XVI (5.0) software. In a significant acquisition of Elekta software, Providence also will begin a system-wide conversion of its existing oncology information system to MOSAIQ® Oncology Information System. Installation of the Elekta systems is set to begin immediately, continuing through the end of 2016.

Elekta to Launch Elekta Healthcare Analytics

At the Healthcare Information and Management Systems Society's 2015 conference (HIMSS15), Elekta will introduce Elekta Healthcare Analytics, a solution for accelerating data analysis to improve clinical, operational and financial decision making. HIMSS15 convenes April 12-15, in Chicago. Elekta Healthcare Analytics is a Knowledge Management solution by Elekta that will enable physicians to harness the vast amount of data available in the health care enterprise. It comprises analytical tools that uncover new ways to: Reduce costs, eliminate inefficiencies and identify potential quality improvements; Manage and measure resource utilization; Standardize care across small and large networks, monitoring care patterns and operational trends; Improve patient satisfaction, tailor patient outreach and manage clinical trial groups and other patient populations.

Elekta Issues SEK 1 Billion Bond with 5 Year Maturity

Elekta issued a SEK 1 billion bond, with five year maturity, under its existing Medium Term Note Program with a total limit of SEK 5 billion. The first tranche of SEK 300 million has a fixed coupon rate of 1.580% paid annually and the second tranche of SEK 700 million has a floating interest rate of 3 months STIBOR plus an interest margin of 1.20% paid quarterly.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKTAB:SS kr83.80 SEK -1.00

EKTAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Accuray Inc $9.00 USD -0.10
American Shared Hospital Services $2.83 USD +0.03
Eckert-Ziegler Bebig €1.28 EUR -0.014
MRI Interventions Inc $1.12 USD +0.02
RaySearch Laboratories AB kr79.50 SEK +0.25
View Industry Companies
 

Industry Analysis

EKTAB

Industry Average

Valuation EKTAB Industry Range
Price/Earnings 30.1x
Price/Sales 2.8x
Price/Book 4.9x
Price/Cash Flow 28.8x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEKTA AB-B SHS, please visit www.elekta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.